These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18702650)

  • 21. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial.
    Goldstein JL; Johanson JF; Suchower LJ; Brown KA
    Am J Gastroenterol; 2005 Dec; 100(12):2650-7. PubMed ID: 16393215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.
    Katz PO; Ginsberg GG; Hoyle PE; Sostek MB; Monyak JT; Silberg DG
    Aliment Pharmacol Ther; 2007 Mar; 25(5):617-28. PubMed ID: 17305763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients.
    Rezailashkajani M; Roshandel D; Shafaee S; Zali MR
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):499-506. PubMed ID: 17489061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open non-comparative clinical study for the evaluation of safety and efficacy of esomeprazole in patients of reflux oesophagitis in Indian population.
    Dinakaran NH; Rajkumar JS; Potdar NP; Desai A
    J Indian Med Assoc; 2002 Oct; 100(10):624-6. PubMed ID: 12452520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
    van Zanten SV; Armstrong D; Chiba N; Flook N; White RJ; Chakraborty B; Gasco A
    Am J Gastroenterol; 2006 Sep; 101(9):2096-106. PubMed ID: 16817845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On-demand therapy for Los Angeles grade A and B reflux esophagitis: esomeprazole versus omeprazole.
    Kao AW; Sheu BS; Sheu MJ; Chang YM; Huang SF; Chuang CH; Lai YL; Kao YH
    J Formos Med Assoc; 2003 Sep; 102(9):607-12. PubMed ID: 14625604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus.
    Vieth M; Kulig M; Leodolter A; Nauclér E; Jaspersen D; Labenz J; Meyer-Sabellek W; Lind T; Willich S; Malfertheiner P; Stolte M
    Aliment Pharmacol Ther; 2006 Jan; 23(2):313-9. PubMed ID: 16393312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients.
    Tulassay Z; Stolte M; Sjölund M; Engstrand L; Butruk E; Malfertheiner P; Dite P; Tchernev K; Wong BC; Gottlow M; Eklund S; Wrangstadh M; Nagy P
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):526-36. PubMed ID: 18467912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Yokota K; Oguma K; Okada H; Yamamoto K
    J Gastroenterol Hepatol; 2009 Jan; 24(1):107-13. PubMed ID: 18823429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
    DelGaudio JM; Waring JP
    Laryngoscope; 2003 Apr; 113(4):598-601. PubMed ID: 12671413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study.
    Malfertheiner P; Nocon M; Vieth M; Stolte M; Jaspersen D; Koelz HR; Labenz J; Leodolter A; Lind T; Richter K; Willich SN
    Aliment Pharmacol Ther; 2012 Jan; 35(1):154-64. PubMed ID: 22070159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of acid suppression on gastric myoelectrical activity in GERD.
    Chen CL; Yi CH; Kuo TB; Yang CC
    Hepatogastroenterology; 2008; 55(85):1353-5. PubMed ID: 18795687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole.
    Goldstein JL; Johanson JF; Hawkey CJ; Suchower LJ; Brown KA
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1101-11. PubMed ID: 17894652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment.
    Giannini EG; Zentilin P; Dulbecco P; Vigneri S; Scarlata P; Savarino V
    Am J Gastroenterol; 2008 Feb; 103(2):267-75. PubMed ID: 18289194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis.
    Cheng H; Tsai YC; Chen WY; Chang WL; Cheng HC; Sheu BS
    Surg Endosc; 2011 Aug; 25(8):2478-86. PubMed ID: 21298521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and endoscopic evaluation of gastroesophageal reflux disease in patients successfully treated with esomeprazole.
    da Silva EP; Nader F; Quilici FA; Eisig JN; Zaterka S; Meneghelli U
    Arq Gastroenterol; 2003; 40(4):262-7. PubMed ID: 15264050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.